Why is Concord Biotech falling/rising?

As of 11-Jul, Concord Biotech Ltd is experiencing a decline in its stock price, currently at 1,795.00, which reflects a decrease of 5.1 or 0.28%. The stock has underperformed its sector by 0.86% today and has been on a consecutive downward trend for the last two days, resulting in a total decline of 1.34% during this period. Over the past week, the stock has shown a modest gain of 3.18%, but it has significantly underperformed over the last month with a drop of 16.02%. Despite having strong long-term fundamentals, including a healthy return on equity and impressive growth in operating profit, the stock's recent performance is hindered by falling investor participation, as evidenced by a 57.27% decrease in delivery volume compared to the five-day average.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has seen a slight decline of 1.12% over the past week. While Concord Biotech's year-to-date performance shows a significant drop of 18.78%, the Sensex has gained 5.58% during the same period, indicating a challenging environment for the stock relative to the market. The increase in institutional investor participation, with a 0.52% rise in their stake, suggests a potential for future stability; however, the current liquidity and trading volume issues may be contributing to the stock's downward pressure in the short term.